Home / Products / Formulations / Svizera Healthcare / Ace / Drovera MF
 

DROVERA MF:

 
 
 
   
   
   
 
 



 
   
 
     
     
 
  Composition
   
  Each tablet of DROVERA MF contains:
  Drotaverine HCl....80 mg
Mefenamic Acid....250 mg
   
   
  Therapeutic Indications & Usage
   
  DROVERA MF is indicated for symptomatic relief of colics such as intestinal, biliary and ureteric, as well as for spasmodic dysmenorrhea.
   
   
  Contraindications
   
  DROVERA MF should not be used in patients who have previously exhibited hypersensitivity to its ingredients, or another NSAID. It is contraindicated in presence of active ulceration or chronic inflammation of either the upper or lower gastrointestinal tract, preexisting renal disease due to mefenamic acid.
   
  DROVERA MF is contraindicated in pregnancy especially in the third trimester; it is strictly not advocated for small children less than 6 months, and during lactation.
   
   
  Precautions
   
  DROVERA MF should be administered during the first 6 months of pregnancy only if strictly required.
   
   
  Warnings
   
  Mefenamic acid (in DROVERA MF) can cause reduced renal blood flow in presence of impaired renal function, heart failure, liver dysfunction, in those taking concomitant diuretics, and in the elderly.
   
  It is unknown whether drotaverine is excreted in human breast milk, and hence the use of DROVERA MF during lactation must be if only strictly required. Mefenamic acid (in DROVERA MF) should be co-administered with caution along with oral anticoagulants.
   
   
  Adverse Reactions
   
  The most frequently reported adverse reactions associated with the use of mefenamic acid (in DROVERA MF) are diarrhea, nausea with or without vomiting, and abdominal pain. Other GI reactions less frequently reported include anorexia, pyrosis, flatulence and constipation. GI ulceration with and without hemorrhage can also occur with mefenamic acid (in DROVERA MF).
   
  Mefenamic acid (in DROVERA MF) can cause hypersensitivity reactions; central nervous disturbances like drowsiness, dizziness, nervousness, headache, blurred vision, insomnia and hematopoietic disturbances.
   
  As with other NSAIDs, renal failure, including papillary necrosis, is a possibility with mefenamic acid (in DROVERA MF) administration. Eye complaints, mild hepatic toxicity, perspiration, and an increased need for insulin in diabetics are possible consequences of mefenamic acid (in DROVERA MF) administration.
   
  The adverse reactions incidence due to drotaverine is 3%, but these mainly occur following IV administration. Oral drotaverine (in DROVERA MF) has only 0.9% adverse event incidence. Since, it is a direct spasmolytic, drotaverine (in DROVERA MF) does not have any anticholinergics side effect. 96% of those administered drotaverine (as DROVERA MF) tolerate the drug very well.
   
  Hypotonia, hypotension, headache, vertigo, nausea, tachycardia, palpitations and porphyria are other reactions reported due to drotaverine (in DROVERA MF).
   
   
  Recommended Dosage & Administration
   
  ADULTS:
  1 DROVERA MF Tab tid, or as prescribed.
   
  ELDERLY CHILDREN:
  ½-1 DROVERA MF Tab tid, or as prescribed.
  Therapy should not exceed one week.
   
   
  Presentations
   
  DROVERA MF Tablets: Blisters of 10s.
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
         
 
"Maneesh" Pharmaceuticals   |  Manufacturing Excellence  |   International Presence  |  Products
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh